Partial splenic embolization as pretreatment for antiviral therapy in hepatitis C virus infection
(2005) In European Journal of Gastroenterology and Hepathology 17(11). p.1153-1155- Abstract
- Antiviral therapy in hepatitis C virus (HCV) infection is limited by haematological side-effects, especially thrombocytopenia and leucopenia. The pancytopenia associated with liver cirrhosis has multifactorial causes, but hypersplenism seems to be a major contributor, especially regarding thrombocytopenia. The use of PSE as a 'Pretreatment' in order to make more patients with HCV-induced cirrhosis and pancytopenia suitable for antiviral therapy using ribavirin and pegylated interferon is a new, promising concept. The setting needs further investigation in prospective, longitudinal studies, in order to evaluate safety, define patient selection criteria, the timing between the PSE procedure and the antiviral therapy and to evaluate the... (More)
- Antiviral therapy in hepatitis C virus (HCV) infection is limited by haematological side-effects, especially thrombocytopenia and leucopenia. The pancytopenia associated with liver cirrhosis has multifactorial causes, but hypersplenism seems to be a major contributor, especially regarding thrombocytopenia. The use of PSE as a 'Pretreatment' in order to make more patients with HCV-induced cirrhosis and pancytopenia suitable for antiviral therapy using ribavirin and pegylated interferon is a new, promising concept. The setting needs further investigation in prospective, longitudinal studies, in order to evaluate safety, define patient selection criteria, the timing between the PSE procedure and the antiviral therapy and to evaluate the long-term results. The setting needs further investigation in prospective, longitudinal studies, in order to evaluate safety, define patient selection criteria, the timing between the PSE procedure and the antiviral therapy and to evaluate the long-term results. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/898723
- author
- Pålsson, Birger LU and Verbaan, Hans LU
- organization
- publishing date
- 2005
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- spleen, ribavirin, embolization, partial splenic, interferon, hypersplenism, cirrhosis, hepatitis C
- in
- European Journal of Gastroenterology and Hepathology
- volume
- 17
- issue
- 11
- pages
- 1153 - 1155
- publisher
- Lippincott Williams & Wilkins
- external identifiers
-
- wos:000233367700001
- pmid:16215425
- scopus:27344438027
- ISSN
- 1473-5687
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Emergency medicine/Medicine/Surgery (013240200)
- id
- bf5aeb67-5784-4ff5-9087-cfbbdd751c18 (old id 898723)
- alternative location
- http://www.eurojgh.com/pt/re/ejgh/pdfhandler.00042737-200511000-00001.pdf;jsessionid=HTfW27vrN9byg5pQlYsvwKd4tqmJ92l2DsSRXztvnsnJVG6hYcHr!-1036421505!181195629!8091!-1
- date added to LUP
- 2016-04-01 11:59:25
- date last changed
- 2022-01-26 21:11:46
@article{bf5aeb67-5784-4ff5-9087-cfbbdd751c18,
abstract = {{Antiviral therapy in hepatitis C virus (HCV) infection is limited by haematological side-effects, especially thrombocytopenia and leucopenia. The pancytopenia associated with liver cirrhosis has multifactorial causes, but hypersplenism seems to be a major contributor, especially regarding thrombocytopenia. The use of PSE as a 'Pretreatment' in order to make more patients with HCV-induced cirrhosis and pancytopenia suitable for antiviral therapy using ribavirin and pegylated interferon is a new, promising concept. The setting needs further investigation in prospective, longitudinal studies, in order to evaluate safety, define patient selection criteria, the timing between the PSE procedure and the antiviral therapy and to evaluate the long-term results. The setting needs further investigation in prospective, longitudinal studies, in order to evaluate safety, define patient selection criteria, the timing between the PSE procedure and the antiviral therapy and to evaluate the long-term results.}},
author = {{Pålsson, Birger and Verbaan, Hans}},
issn = {{1473-5687}},
keywords = {{spleen; ribavirin; embolization; partial splenic; interferon; hypersplenism; cirrhosis; hepatitis C}},
language = {{eng}},
number = {{11}},
pages = {{1153--1155}},
publisher = {{Lippincott Williams & Wilkins}},
series = {{European Journal of Gastroenterology and Hepathology}},
title = {{Partial splenic embolization as pretreatment for antiviral therapy in hepatitis C virus infection}},
url = {{http://www.eurojgh.com/pt/re/ejgh/pdfhandler.00042737-200511000-00001.pdf;jsessionid=HTfW27vrN9byg5pQlYsvwKd4tqmJ92l2DsSRXztvnsnJVG6hYcHr!-1036421505!181195629!8091!-1}},
volume = {{17}},
year = {{2005}},
}